- The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 10% during intraday trading. This is why it happened.
The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) – a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers – increased by over 10% during intraday trading. Investors are responding positively to Plus Therapeutics announcing the first patient in the eighth cohort of the Phase 1 dose-escalation ReSPECT-GBM clinical trial for recurrent glioblastoma (rGBM) has been successfully treated. And the present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort.
Twenty-two patients across 8 dosing cohorts have been treated in the ReSPECT trial to date. And so far, no treatment-emergent dose-limiting toxicities have been observed, despite absorbed radiation doses to the tumor of up to 740 Gray.
“The ReSPECT-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile. We plan to provide an update on the trial in the fourth quarter of 2021.”
— Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.